SFA Therapeutics, Inc
A Major Advancement in Treating Chronic Inflammatory Diseases and Cancer
SFA Therapeutics is an early stage biotech with a novel immunomodulatory platform focused on chronic inflammatory diseases and oncogenesis. Our drugs modulate the immune system, controlling inflammation and cancer. Primary targets include autoimmune diseases like psoriasis, and liver diseases, like Hepatitis B, NASH, & liver cancer. Other potential targets are uveitis, CLL/AML, and CAR-T side effects. We are in Ph 1b. We plan to change Medicine.